Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial - 30/10/18
Doi : 10.1016/j.ahj.2018.07.013
Salvatore Brugaletta, MD, PhD a, ⁎ 
, Josep Gomez-Lara, MD, PhD b, Juan Caballero, MD, PhD c, Luis Ortega-Paz, MD a, Luis Teruel, MD b, Miriam Jimenez Fernandez, MD c, Rafael Romaguera, MD b, Vicente Alcalde Martinez, MD c, Marcos Ñato, MD b, Eduardo Molina Navarro, MD c, Joan-Antoni Gomez-Hospital, MD, PhD b, Concepcion Correa Vilches, MD c, Maria Joyera, BS d, Angel Cequier, MD, PhD b, Dominick J Angiolillo, MD, PhD e, Manel Sabate, MD, PhD a
, Josep Gomez-Lara, MD, PhD b, Juan Caballero, MD, PhD c, Luis Ortega-Paz, MD a, Luis Teruel, MD b, Miriam Jimenez Fernandez, MD c, Rafael Romaguera, MD b, Vicente Alcalde Martinez, MD c, Marcos Ñato, MD b, Eduardo Molina Navarro, MD c, Joan-Antoni Gomez-Hospital, MD, PhD b, Concepcion Correa Vilches, MD c, Maria Joyera, BS d, Angel Cequier, MD, PhD b, Dominick J Angiolillo, MD, PhD e, Manel Sabate, MD, PhD a a Cardiovascular Institute, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
b Heart Disease Institute, Bellvitge University Hospital, University of Barcelona, IDIBELL, Barcelona, Spain
c Hospitales Universitarios San Cecilio y Virgen de las Nieves, Granada, Spain
d Hospital Clinic, Barcelona, Spain
e Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA
⁎Reprint requests: Salvatore Brugaletta, MD, PhD, FESC, c/ Villarroel 170, 08036, Cardiovascular Institute, Cardiology department, University Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.Cardiovascular Institute, Cardiology department, University Hospital Clinic, IDIBAPS, University of Barcelonac/ Villarroel 170Barcelona08036Spain
Abstract |
Coronary vascular function of a chronic coronary total occlusion (CTO) immediately after recanalization is known to be poor. We sought if ticagrelor may augment adenosine-induced coronary blood flow vs. clopidogrel immediately after successful CTO percutaneous coronary intervention (PCI).
Le texte complet de cet article est disponible en PDF.| Dr Brugaletta reports lectures fees from Abbott Vascular; Dr Cequier reports research grants from Abbott Vascular, and Medtronic. Consulting/lectures fees from Abbott Vascular, Medtronic, Boston Scientific, Daiichi-Sankyo, AstraZeneca, Menarini. Dr Angiolillo reports receiving payments as an individual for: (a) Consulting fee or honorarium from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Janssen, Merck, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; (b) Participation in review activities from CeloNova and St. Jude Medical. Institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli-Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions; in addition, Dr Angiolillo is recipient of a funding from the Scott R. MacKenzie Foundation and the NIH/NCATS Clinical and Translational Science Award to the University of Florida UL1 TR000064 and NIH/NHGRI U01 HG007269, outside the submitted work. Other authors do not have any conflict of interest. |
© 2018
Elsevier Inc. Tous droits réservés.
Vol 204
P. 205-209 - octobre 2018 Retour au numéro
Article précédent
- Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial
- Robert J. Mentz, Christopher M. O'Connor, Bradi B. Granger, Hongqiu Yang, Chetan B. Patel, Karen E. Steinhauser, Mona Fiuzat, Kimberly S. Johnson, Kevin J. Anstrom, Gwen C. Dodson, Donald H. Taylor, Daniel B. Mark, James A. Tulsky, Joseph G. Rogers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?